Corporate
Nov. 12, 2012
Stradling handles $425 million acquisition of medical technology company
In the deal to be finalized later this month, Boston Scientific Inc. will acquire Stradling client Vessix Vascular Inc. as part of an effort to expand in the fast-growing market of renal denervation.
Daily Journal Staff Writer
Stradling Yocca Carlson & Rauth PC represented Vessix Vascular Inc. in its $425 million acquisition by leading global medical device company Boston Scientific Inc.
In the deal, to be finalized later this month, Boston Scientific will acquire Vessix as part of its plan to expand in the fast-growing market of renal denervation, a procedure that involves burning nerves on the kidney to redu...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In